NCT01846195 is a NA clinical trial of CM 1500 in Blood Loss, sponsored by Zynex Monitoring Solutions.

Who is sponsoring NCT01846195?

NCT01846195 is sponsored by Zynex Monitoring Solutions.

What drugs are being tested in NCT01846195?

Interventions in NCT01846195: CM 1500.

What condition does NCT01846195 study?

NCT01846195 studies Blood Loss.

Is NCT01846195 still recruiting?

NCT01846195 is currently completed. Last updated 9 November 2022.

Are results published for NCT01846195?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2022-11-09 · How we verify

NCT01846195

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of the Zynex Blood Volume Monitor in Healthy Adult Patients During a Blood Draw

Completed NA Results posted Last updated 9 November 2022

What this trial tests

NA trial testing CM 1500 in Blood Loss in 50 participants. Completed in 20 March 2013.

Timeline

6 June 2012

Primary endpoint
20 March 2013

20 March 2013

Quick facts

Lead sponsor	Zynex Monitoring Solutions
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	other
Enrollment	50
Start date	6 June 2012
Primary completion	20 March 2013
Estimated completion	20 March 2013
Sites	1 location across United States

Drugs / interventions tested

CM 1500

Conditions studied

Blood Loss — all drugs for Blood Loss →

Sponsor

Zynex Monitoring Solutions

Who can join

Adults 18 to 35, any sex, with Blood Loss. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Detect by Non-invasive Monitoring a Change in Blood Volume During a Whole Blood Draw Primary · At study completion (completion of blood draw)

Detection by non-invasive monitoring a change in blood volume (yes or no) during a whole blood draw

Group	Value	95% CI
no Blood Draw	0
Blood Draw	45

Adverse events — posted to ClinicalTrials.gov

Time frame: Adverse event data was collected through the completion of the study. Adverse events per subject may have occurred during the blood draw or within 24 hours following with any potential reaction to electrode adhesive.. Reporting threshold: 0%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

no Blood Draw

Serious: 0/5 (0%)

Deaths: 0/5

Blood Draw

Serious: 0/45 (0%)

Deaths: 0/45

Other adverse events (1 terms — click to expand)

Reaction	System	no Blood Draw	Blood Draw
Vasovagal Reaction to Blood Draw	General disorders	—	—

Data from ClinicalTrials.gov NCT01846195 adverse events section.

Sponsor's own description

Non-invasive monitoring to measure changes in blood volume.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Blood Loss

Currently open trials in the same condition.

NCT07526311 — Reducing Blood Loss During Myomectomy:Uterine Artery Ligation Vs Pericervical Tourniquet · NA · recruiting
NCT07089251 — The Perioperative Outcome of Epinephrine Infusion and Tranexamic Acid in Knee Arthroplasty Surgery · Phase 4 · recruiting
NCT05488457 — Oxytocin Pharmacokinetics and Pharmacodynamics · Phase 2 · recruiting
NCT06802874 — Maternal-fetal Outcomes of Genital Blood Loss Beyond 18 Weeks of Pregnancy · recruiting
NCT06903299 — Prospective Investigation of Intra-Articular Tranexamic Acid Use in Elective Hip Arthroplasty · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01846195 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zynex Monitoring Solutions
Last refreshed: 9 November 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01846195.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing